Acrux Ltd has released a press release.
Axiron License Agreement Terminated
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Acrux
- Appendix 4E and 2017 Financial Report
- Teva Launches Generic Version of Axiron in United States
- Axiron Net Sales Quarter to 30 June 2017
- Axiron Generic Launched In The United States
- Institution of IPR Proceeding Against Key Jublia Patent
Later from Acrux
- Axiron Net Sales Quarter to September 2017
- Axiron Patents Appeal Decision
- Axiron Net Sales Quarter to December 2017
- Appendix 4D and Half-Year Report to 31 December 2017
- Acrux Submits First-To-File Generic of Jublia
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux